abstract: The nuclear factor of activated T-cells (NFAT) c1 has been shown to be essential for @entity0 -dependent upregulation of @entity4 ( @entity4 ) I/b expression during skeletal muscle fiber type transformation. Here, we report activation of @entity3 in @entity0 -ionophore-treated C2C12 myotubes and electrostimulated soleus muscle. Activated @entity1 enhanced @entity5 -dependent upregulation of a -2.4 kb MyHCI/b promoter construct without affecting subcellular localization of endogenous @entity5 . Instead, @entity1 -augmented phosphorylation of transcriptional coactivator @entity2 , promoted its recruitment to @entity5 and increased @entity5 -DNA binding to a NFAT site of the MyHCI/b promoter. In line, inhibition of @entity1 signaling abolished the effects of @entity2 . Comparison between wild-type @entity2 and an acetyltransferase-deficient mutant (p300DY) indicated increased @entity5 -DNA binding as a consequence of @entity2 -mediated acetylation of @entity5 . Activation of the MyHCI/b promoter by @entity2 depends on two conserved acetylation sites in @entity5 , which affect DNA binding and transcriptional stimulation. @entity5 acetylation occurred in @entity0 -ionophore treated C2C12 myotubes or electrostimulated soleus. Finally, endogenous MyHCI/b gene expression in C2C12 myotubes was strongly inhibited by p300DY and a mutant deficient in ERK phosphorylation sites. In conclusion, @entity1 -mediated phosphorylation of @entity2 is crucial for enhancing @entity5 transactivation function by acetylation, which is essential for @entity0 -induced MyHCI/b expression.

title: Extracellular signal-regulated kinase 1/2-mediated phosphorylation of XXXX enhances @entity4 I/beta gene expression via acetylation of nuclear factor of activated T cells c1.

answer: @entity2


abstract: BACKGROUND: The Obesity Surgery Mortality Risk Score (OS- @entity2 ) was developed using data from 1995 to 2004; it has yet to be validated for more recent @entity0 in integrated delivery system settings. The objective of this study was to validate the OS- @entity2 using data from electronic health records in a distributed data network. METHODS: We conducted a retrospective cohort study of 3,817 adults who underwent an open (21.4%) or laparoscopic (78.6%) gastric bypass surgery between 2005 and 2007 in the Scalable Partnering Network. Our main outcome was all-cause mortality during the 90 days after surgery. We scored @entity0 ' risk of mortality by adding characteristics according to the OS- @entity2 (i.e., 1 point for each predictor). RESULTS: Sixteen of 3,817 (0.42/100; 95% CI, .24-.68) @entity0 died within 90 days. The OS- @entity2 discriminated low-risk and high-risk @entity0 effectively: low-risk (2 of 1,654 @entity0 ; .12 @entity1 /100 @entity0 ), intermediate-risk (10 of 2,008 @entity0 ; .50 @entity1 /100 @entity0 ), and high-risk (4 of 155 @entity0 ; 2.58 @entity1 /100 @entity0 ). High-risk @entity0 were 21.3 times more likely to die in the first 90 days after surgery than low-risk @entity0 (risk ratio = 21.3; 95% CI, 3.9-115.6). CONCLUSION: In these 10 U.S. healthcare delivery systems, the OS- @entity2 appears valid-albeit with the caveat that we observed a small number of @entity1 . The OS- @entity2 appears useful for identifying the small fraction of @entity0 at high risk for 90-day mortality after open and laparoscopic RYGB.

title: Predicting 90-day mortality after bariatric surgery: an independent, external validation of the OS- XXXX prognostic risk score.

answer: @entity2


abstract: A decline in age-adjusted ischemic @entity2 mortality has been observed in the United States during the past two decades. Among the leading explanatory hypotheses is improvement in the major known risk factors for @entity5 and @entity1 in the general population, specifically @entity3 , smoking, and lipid levels. To better understand risk factor trends, the @entity5 ( @entity5 ) began systematic risk factor surveys of the Minneapolis-St Paul population in 1980, (population 1.99 million). The metropolitan area was divided into 704 subareas (clusters) of approx. 1000 households each, utilizing geographic boundaries. In a two-stage cluster sampling technique, 40 subareas were randomly chosen and mapped. Approximately 8.75% of households were chosen from each subarea and selected residents age 25-74 years invited to participate. A total 4451 individuals participated in 1980-82. The response rate for a home interview was 81.9 and 84.4% for a subsequent survey center visit, producing an overall response of 69.1%. The age and sociodemographic characteristics of the survey @entity0 were similar to those found in the 1980 census. The prevalence of @entity3 was 18.3% in this population with 76.0% taking medications and 65.0% controlled. Total @entity4 and HDL- @entity4 levels demonstrated age and sex differences similar to those reported elsewhere. Current smoking of cigarettes was equally prevalent in @entity0 (34.5%) and @entity0 (33.5%) although more @entity0 were former smokers (35.2 vs 20.6%). @entity5 with the National HANES II data (1976-80) indicates lower regular cigarette smoking among Minnesota males, with similar rates in females. Minnesota residents had better control of @entity3 .

title: Population risk of XXXX : the @entity5 .

answer: @entity2


abstract: UNASSIGNED: The occurrence of a kidney transplant @entity1 is a rare but serious issue with a double risk: the return to dialysis and the development of @entity1 . Publications on this topic are mainly case reports. The purpose of this review was to report an exhaustive literature review of functional graft @entity5 to highlight the impact of @entity1 on the renal graft outcomes. 201 de novo @entity4 in functional renal grafts from 69 publications were included. Incidence was estimated at 0.18%. Graft @entity1 were mostly asymptomatic (85.9%). Whatever the discovery circumstances of graft @entity1 , they were mostly documented by graft ultrasounds supplemented by CT-scanning or MR imaging. Nephron sparing surgery (95 @entity0 ) was the first treatment performed followed by radiofrequency ablation (38 @entity0 ) and cryotherapy (10 @entity0 ). The most common @entity1 graft histology was @entity5 (46.4%), followed by @entity6 (43.7%). Specific mortality was 2.9% with 6 deaths. Renal graft cell @entity2 is a rare pathology with a low specific @entity3 . When possible, conservative treatment should be the first choice.

title: XXXX in functional renal graft: Toward ablative treatments.

answer: @entity5


abstract: The objective of this study was to determine the immunoexpression pattern of the mitogen-activated protein kinase (MAPK), and related signalling proteins [ @entity8 ( @entity8 ), phospholipase Cgamma (PLCgamma)], in @entity3 multi-forme, and to investigate their prognostic value. @entity5 -embedded biopsy samples from 26 @entity0 [13 @entity0 with long-term survival (LTS; N=13; median 28 months, range 13-76 months), and, for comparison, 13 @entity0 with short-term survival (STS; N=13; median 7 months, range 1-12 months)] were investigated for the immunoexpression of MAPK, the activated pMAPK, @entity8 , PLCgamma, @entity4 , and @entity6 . Additionally, the @entity7 proliferation index was determined. The immunoexpression pattern were related to clinical data, including analysis of their prognostic value using the Cox-proportional hazard model. No significant differences were found between STS and LTS in terms of age, Karnofsky performance status, and treatment. Whereas @entity4 expression did not differ between STS and LTS and does not influence survival, expression of MAPK and activated pMAPK was significantly correlated with survival time. The percentage of pMAPK expressing cells correlated strongly with the percentage of @entity7 positive cells. Furthermore, survival in @entity0 with @entity1 expressing @entity8 or PLCgamma was significantly shorter. No differences were found for @entity6 expression. Our findings indicate that the MAPK pathway is correlated with proliferation in @entity2 , and that @entity0 subgroups exist, in which expression of MAPK-related signalling proteins ( @entity8 , PLCgamma) is associated with poorer prognosis. These @entity0 subgroups may benefit from additional chemotherapeutic agents which specifically inhibit these signalling proteins.

title: Prognostic relevance of MAPK expression in XXXX multiforme.

answer: @entity3


abstract: UNASSIGNED: Adeno-associated viruses (AAVs) have become powerful tools in neuroscience for both basic research and potential therapeutic use. They have become especially important tools for optogenetic experiments based on their ability to achieve transgene expression in postmitotic neurons with regional selectivity. With the use of appropriate promoter elements they can achieve cellular specificity as well. One population of neurons that plays a central role in @entity0 neurodegenerative and @entity2 diseases are the @entity3 neurons of the midbrain. To study these neurons in vivo with advanced techniques it would be highly advantageous to characterize an appropriate specific promoter. To this end we have characterized a 2.5-kb sequence of the @entity1 @entity4 hydroxylase ( @entity5 ) promoter. The @entity5 (2.5) promoter induced expression of the fluorescent reporter protein mCherry in SN @entity3 neurons. Although it showed excellent specificity in cortex and striatum, where no reporter expression was observed, in the SN region many neurons expressed reporter but not @entity5 . We show that some of the @entity5 negativity is due to the suppression of its expression by the transgene. We conclude that @entity5 (2.5) does preferentially label @entity3 neurons but its specificity is not complete within the substantia nigra and caution must be used.

title: A quantitative evaluation of a 2.5-kb @entity1 @entity4 hydroxylase promoter to target expression in ventral mesencephalic XXXX neurons in vivo.

answer: @entity3


abstract: BACKGROUND/AIMS: To examine the reproducibility of lesion dimensions of the @entity2 ( @entity2 ) in neovascular @entity3 ( @entity3 ) with polarisation-sensitive optical coherence tomography (PS- @entity5 ), specifically imaging the @entity2 . METHODS: Twenty-six @entity0 (28 eyes) with @entity3 were included in this study, and examined by a PS- @entity5 prototype. Each @entity0 was scanned five times at a 1-day visit. The PS- @entity5 B-scan located closest to the macular centre presenting with @entity2 @entity1 was identified, and the longitudinal diameter of the lesion was quantified manually using AutoCAD 2008. This procedure was followed for the identical B-scan position in all five scans per eye and @entity0 . Reproducibility of qualitative changes in PS- @entity5 was evaluated. Interobserver variability was assessed. Results were compared with intensity-based spectral-domain @entity5 (SD- @entity5 ) imaging. RESULTS: Mean variability of all @entity1 lesion dimensions was 0.10   mm (SD  =0.06   mm). Coefficient of variation (SD  /mean) was 0.06 on average (SD  =0.03). Interobserver variability assessment showed a mean difference of 0.02   mm across all @entity0 regarding @entity2 lesion size evaluation (paired t test: p=0.38). Spearman correlation coefficient was r=0.98, p<0.001. Results revealed a good overall reproducibility of    90%. PS- @entity5 specifically detected the @entity2 in all eyes compared with conventional intensity-based SD- @entity5 that was not capable to clearly identify @entity2 @entity1 in 25 eyes (89.3%, p<0.01). CONCLUSIONS: PS- @entity5 offers good reproducibility of @entity2 @entity1 assessment in @entity3 , and may be suitable for precise @entity2 evaluation in clinical practice. PS- @entity5 unambiguously identifies @entity2 changes in @entity4 compared with intensity-based SD- @entity5 that does not identify the @entity2 status reliably.

title: Polarisation-sensitive @entity5 is useful for evaluating retinal pigment epithelial lesions in XXXX with @entity3 .

answer: @entity0


abstract: BACKGROUND: The significance of cardiac troponin I (TnI) levels in @entity0 with acute @entity2 remains unclear. METHODS: Data were prospectively collected on 1718 @entity0 with acute @entity2 (2009-2010). @entity0 with positive TnI (peak TnI >= 0.1  g/L) were assigned to the @entity4 ( @entity4 ) group if they met diagnostic criteria. The remaining @entity0 with positive TnI were assigned to the no- @entity4 group. @entity0 were followed up for 1.4    1.1 years. Primary outcome was inhospital and long-term all-cause mortality. RESULTS: Positive TnI was present in 309 @entity0 (18%), 119 of whom (39%) were classified as having @entity4 . Positive TnI was independently associated with older age, @entity1 , smoking, peripheral @entity3 , @entity5 , higher systolic blood pressure, higher serum @entity6 , and lower heart rate (P < .01). @entity0 with @entity4 had the highest inpatient mortality (P < .001) and the lowest survival rate by Kaplan-Meier analysis (P < .0001). Peak TnI greater than or equal to 0.5  g/L, particularly if satisfying criteria for @entity4 , was independently associated with long-term mortality (P < .0001); peak TnI less than 0.5  g/L alone was not when adjusted for covariates. CONCLUSION: Positive TnI greater than or equal to 0.5  g/L in @entity0 with acute @entity2 was independently associated with worse outcomes. @entity0 with diagnosis of @entity4 represent a particularly high-risk subgroup.

title: The prognostic significance of troponin I elevation in acute XXXX .

answer: @entity2


abstract: OBJECTIVE: To estimate the cost-effectiveness of three @entity8 ( @entity10 , @entity9 , and @entity4 ) and generic @entity6 in the treatment of nonneutropenic adult @entity0 with @entity7 and/or @entity1 in intensive care units in Spain. MATERIALS AND METHODS: A decision-tree model was applied. The success and safety (hepatic and renal adverse effects) of first-line treatments were obtained from meta-analyses and systematic reviews of clinical trials. In the case of failure, a second-line treatment (liposomal @entity5 after the @entity8 , or one of the @entity8 after @entity6 ) was administered. The duration of the treatments (14 days total) was established by a panel of clinical experts using the Delphi method and according to @entity3 Society of America guidelines. The cost of the medications and renal @entity2 were considered. Deterministic and probabilistic sensitivity analysis using Monte Carlo simulations were carried out. RESULTS: The total cost of the treatment of @entity7 and/or @entity1 with @entity10 , @entity9 , @entity4 , and @entity6 was    5,483,    5,968,    6,231, and    2,088, respectively. @entity10 was the dominant treatment (more effective, less expensive) compared to @entity4 and @entity9 . The cost of achieving one more @entity0 successfully treated with @entity10 , @entity9 , and @entity4 compared to @entity6 was    17,199,    23,962, and    27,339, respectively. The result remained stable, despite modification of the duration of the first-line and second-line treatments, as well as most of the dosing regimens. The probabilistic analysis also remained stable. CONCLUSION: In accordance with this economic study, @entity10 would produce savings and would be the dominant treatment compared with @entity4 and @entity9 in nonneutropenic adult @entity0 with @entity7 and/or @entity1 in intensive care units in Spain.

title: Cost-effectiveness of three @entity8 and XXXX in the treatment of @entity7 and/or @entity1 in nonneutropenic adult @entity0 .

answer: @entity6


abstract: An HPLC method was developed for the determination of @entity1 (NHDC) in foods. A solid sample was extracted with @entity0 . The extract was evaporated and the residue was dissolved in @entity0 -water (2:8) mixture. In the case of fluid sample, the sample solution was prepared by dilution with @entity0 -water (2:8) mixture. The sample solution was cleaned up on a C18 cartridge. The cartridge was washed with water and @entity0 -water (3:7) mixture, and NHDC was eluted with @entity0 -water (7:3) mixture. NHDC in the eluate was separated on an ODS column and determined with a UV detector (282 nm). The identity of NHDC in foods was confirmed by means of HPLC with a photodiode-array detector. The recoveries of NHDC added to various kinds of foods were 75.2-134%. The determination limit of NHDC was 1 microgram/g.

title: [Determination of XXXX in foods].

answer: @entity1


abstract: @entity1 ( @entity1 ) may be associated with @entity3 . However, emotion recognition mediated by bodily postures has never been examined in these @entity0 . Moreover, several studies have suggested a relation between emotion @entity3 and alexithymia. This is in line with the idea that the ability to recognize emotions requires the individuals to be able to understand their own emotions. Despite a deficit in emotion recognition has been observed in @entity1 @entity0 , the association between @entity3 has received little attention. The aim of this study was, first, to investigate @entity1 @entity0 's abilities to recognize emotions mediated by both facial and bodily expressions and, second, to examine whether any observed @entity2 recognition could be explained by the presence of alexithymia. Thirty @entity0 with @entity1 and 30 healthy matched controls performed experimental tasks assessing emotion discrimination and recognition of facial expressions and bodily postures. Moreover, they completed questionnaires evaluating alexithymia, @entity4 , and fatigue. First, facial emotion recognition and, to a lesser extent, bodily emotion recognition can be impaired in @entity1 @entity0 . In particular, @entity0 with higher disability showed an @entity3 compared with @entity0 with @entity5 and controls. Second, their deficit in emotion recognition was not predicted by alexithymia. Instead, the disease's characteristics and the performance on some cognitive tasks significantly correlated with emotion recognition. @entity3 recognition is a cognitive signature of @entity1 that is not dependent on alexithymia. (JINS, 2014, 19, 1-11).

title: Facial and bodily emotion recognition in XXXX : the role of alexithymia and other characteristics of the disease.

answer: @entity1


abstract: BACKGROUND: Treatment verification and contact elicitation are core approaches used to control the spread of @entity2 ( @entity2 ). Methodology adapted from the @entity1 care continuum is presented as an evaluation and communication tool for STD control activities. METHODS: Sexually transmitted disease surveillance and program data for Los Angeles County in 2013 were used to construct a 2-part continuum to examine syphilis (all stages) and @entity3 outcomes among index @entity0 and elicited contacts. The Index Case Continuum (Part 1) assesses the proportion of @entity0 who were treated, assigned for interview, interviewed, and provided name and locating information for at least 1 contact. The Elicited Contact Continuum (Part 2) assesses the proportion of contacts who were located, interviewed, and treated. RESULTS: Among 3668 @entity0 with syphilis, 97% (n = 3556) were treated, 72% (n = 2633) were interviewed, and 25% (n = 920) provided name and locating information for at least 1 contact. The corresponding numbers for 12,541 @entity3 cases were 95% (n = 11,936), 45% (n = 5633), and 16% (1944), respectively. Among the 1392 contacts elicited from syphilis cases, 53% (n = 735) were either interviewed or determined to not need an interview and 43% (n = 595) were treated. The corresponding numbers for the 2323 contacts elicited from @entity3 cases were 53% (n = 1221) and 46% (n = 1075), respectively. CONCLUSIONS: Adaptation of the @entity1 continuum is a useful tool for evaluating treatment verification and contact elicitation activities. In Los Angeles County, this approach revealed significant drop-offs in the proportion of index cases naming contacts and in the proportion of contacts who are interviewed and treated.

title: Adaptation of the @entity1 Care Continuum as a Method for Evaluating Syphilis and XXXX Control Activities in Los Angeles County.

answer: @entity3


abstract: @entity1 of the glenohumeral joint in early stages and in younger @entity0 are an important problem and present a challenge during clinical decision making. Although prosthetic arthroplasty remains the gold standard for treatment in later stages of the disease, alternatives are desirable in the early stages and in young @entity0 . The purposes of this study are to evaluate the results of arthroscopic debridement and capsular release in @entity0 with grade IV @entity1 of the glenohumeral joint and to determine the factors associated with their success. Sixty-one @entity0 with grade IV @entity1 of the glenohumeral articular surfaces were treated with arthroscopic debridement, with or without arthroscopic capsular release. Standardized data collection was performed at the initial office visit and at the time of final follow-up. Overall outcome was analyzed with regard to @entity0 ' self-assessment of @entity2 , function, improvement, satisfaction, and duration of @entity2 relief. Forty-five of the @entity0 had a minimum follow-up of 2 years. Time-to-event analysis was used to evaluate the duration of @entity2 relief. The mean @entity0 satisfaction score (0 = not satisfied; 10 = completely satisfied) improved from 0.67 preoperatively to 6.28 at final follow-up (P <.0001), with 87% of @entity0 indicating that they would have the surgery again. Although workers' compensation @entity0 obtained inferior results, significant improvement in @entity2 and function was obtained in 88% of all @entity0 (P <.0001). Most @entity0 noted the onset of @entity2 relief within 5 weeks of surgery and obtained a duration of @entity2 relief of 28 months or greater (P <.05). The addition of concomitant procedures, such as acromioplasty, distal clavicle resection, labral debridement, or labral repair, did not have a negative impact on the functional results after arthroscopic debridement and capsular release. In well-selected @entity0 with grade IV @entity1 of the glenohumeral joint, significant improvements in @entity2 relief and function follow arthroscopic debridement of the glenohumeral joint. Arthroscopic capsular release can be added in @entity0 with a loss of passive arcs of shoulder motion. @entity1 greater than 2 cm(2) appear to be associated with return of @entity2 and failure of this procedure.

title: Non-prosthetic management of grade IV XXXX of the glenohumeral joint.

answer: @entity1


abstract: @entity1 ( @entity1 ) is the fifth most common @entity0 worldwide and the third most common @entity0 in Asia. @entity1 has heterogeneous etiologic and molecular profiles and a varied response to therapeutics. The high recurrence rate and curtailed survival in this @entity0 are attributed to its resistance to therapy. The ultimate goal is to develop a more effective personalized therapeutic strategy for @entity1 , but the first step is to develop a system for classifying the disease on the basis of molecular biomarkers. To that end, we performed mRNA and microRNA (miRNA) expression profiling in 100 @entity1 tissues. Clustering analysis of informative genes identified two robust subtypes, which were validated by an independent dataset. The subtype characterized by a @entity0 stem cell-like signature was clinically aggressive and associated with poor survival. Integrated analysis of miRNA and mRNA expression in this subtype showed that @entity7 was expressed at a significantly lower level in these @entity0 than in the other subtype. @entity7 has been shown to directly suppress the expression of @entity8 ( @entity8 ), a key receptor in the signaling pathway of the bone morphogenetic proteins (BMPs), which regulate many stem cell markers as well as the clinically important cytokine @entity2 ( @entity2 ). Increased expression of @entity8 and its downstream genes @entity4 , @entity6 , @entity3 , and @entity2 was associated with shorter survival in a larger cohort of 227 @entity1 cases. Introduction of @entity7 resulted in suppressed @entity0 phenotypes both in vitro and in vivo. CONCLUSION: We identified a clinically aggressive stem cell-like subtype of @entity1 that is characterized by an @entity7 - @entity8 - @entity5 -Wnt circuit. We propose that @entity7 may serve as a prognostic biomarker and therapeutic target for this subtype of @entity1 .

title: Regulatory XXXX - @entity8 / @entity5 circuit defines a @entity0 .

answer: @entity7


abstract: BACKGROUND: Oncology nurses play a crucial role in @entity1 management and must be highly informed to ensure their effective practice in the @entity1 setting. The aim of this study was to determine the baseline level of knowledge and attitudes of oncology nurses regarding @entity1 management. MATERIALS AND METHODS: A cross-sectional survey research design was employed. The sample comprised 58 @entity1 nurses working in Shahid Sadoughi hospital, Yazd, Iran. The ''Nurses Knowledge and Attitudes Survey Regarding @entity2 '' (NKAS) tool and a demographic form were utilized to ascertain the knowledge and attitudes of oncology nurses working in oncology settings. RESULTS: The average correct response rate for oncology nurses was 66.6%, ranging from 12.1% to 94.8%. The nurses mean score on the knowledge and attitudes survey regarding @entity2 management was 28.5%. Results revealed that the mean percentage score overall was 65.7%. Only 8.6% of nurse @entity0 obtained a passing score of 75% or greater. Widespread knowledge deficits and poor attitudes were noted in this study, particularly regard pharmacological management of @entity2 . CONCLUSIONS: The present study provides important information about knowledge deficits in @entity2 management among oncology nurses and limited training regarding @entity2 management. Our results support the universal concern of inadequate knowledge and attitudes of nurses regarding @entity1 . It is suggested educational and quality improvement initiatives in @entity2 management could enhance nurses knowledge in the area of @entity2 and possibly improve practice.

title: Oncology Nurses Knowledge and Attitudes Regarding XXXX Management.

answer: @entity1


abstract: BACKGROUND: Platelet activation and consumption are common in @entity7 @entity0 and are associated with poorer prognosis. Mean platelet volume is a simple surrogate for platelet activation, with higher @entity9 being associated with worse clinical condition on a large array of clinical diagnoses. We therefore aimed to investigate associations between changes in platelet count and mean platelet volume ( @entity9 ) with prognosis and inflammatory cytokine values in @entity7 @entity0 . METHODS: This study prospectively included 84 @entity7 @entity0 . @entity0 were stratified into four groups according to proportional changes in @entity9 (  MPV24h) and platelet count (  Plat24h) in the first 24  hours after admission. Mortality between groups was compared using the    (2) test. Logistic regression was performed using hospital mortality as outcome and Simplified Acute Physiology Score ( @entity10 ),   @entity8 24h and   MPV24h as covariates. Concentrations of the following inflammatory mediators were measured using Miliplex   technology: @entity6 , @entity2 , @entity4 , @entity5 , epidermal growth factor, vascular endothelial growth factor, @entity1 and @entity3 . Cytokine concentrations were compared between groups using the Kruskal-Wallis test with Bonferroni correction. RESULTS: @entity0 in whom @entity9 increased and platelet count decreased had higher mortality rates (46%). According to logistic regression,   MPV24h was independently associated with increased mortality (OR 1.28 per 1% increase; 95% CI 1.08 to 1.48). No strong associations between inflammatory mediators and changes in @entity9 and platelet count were found. CONCLUSION: An increase in @entity9 after admission to an ICU is independently associated with higher hospital mortality.

title: An increase in mean platelet volume after admission is associated with higher mortality in @entity7 XXXX .

answer: @entity0


abstract: BACKGROUND: @entity9 ( @entity9 ) is a rare and lethal disease with few therapeutic options. Preclinical data suggest that the @entity6 ( @entity6 ) pathway could be involved in its progression. METHODS: This open-label, randomized phase 2 trial recruited chemotherapy-naive @entity0 with advanced @entity9 displaying a wild-type (WT) @entity8 status. @entity0 were randomized to @entity3 (1000   mg/m(2) ) and @entity7 (100   mg/m(2) ) with (arm A) or without (arm B) panitumumab (6   mg/kg) for up to 12 cycles. The primary endpoint was progression-free survival (PFS) analyzed in an intention-to-treat fashion. RESULTS: Eighty-nine @entity0 (45 in arm A and 44 in arm B) were enrolled between June 2010 and September 2013. After a median follow-up of 10.1 months, the median PFS was 5.3 months (95% confidence interval, 3.3-7.2 months) in arm A and 4.4 months (95% confidence interval, 2.6-6.2 months) in arm B (P   =   .27). No survival differences were observed: the median overall survival was 9.9 months in arm A and 10.2 months in arm B (P   =   .42). In a subgroup analysis, no differences in PFS according to the site of the primary @entity1 were observed; @entity0 with @entity11 treated with panitumumab may have had a survival benefit in comparison with the control group (15.1 vs 11.8 months, P   =   .13). As for safety, @entity4 was the main adverse event in arm A (80% of the @entity0 ). A higher incidence of @entity5 (55.5% vs 31.8%), @entity2 (22.2% vs 13.6%), and @entity10 (24.4% vs 15.9%) was seen in arm A. CONCLUSIONS: These results confirm the marginal role of anti- @entity6 therapy even for WT @entity8 -selected @entity9 . @entity1 2016;122:574-581.    2015 American @entity1 Society.

title: Panitumumab in combination with XXXX and @entity7 does not prolong survival in wild-type @entity8 advanced @entity9 : A randomized phase 2 trial (Vecti-BIL study).

answer: @entity3


abstract: PURPOSE: To analyze the differences between the intensity-modulated radiotherapy (IMRT), single/partial-arc volumetric modulated arc therapy (SA/PA-VMAT) techniques in treatment planning for locally advanced @entity1 . MATERIALS AND METHODS: 12 @entity0 were retrospectively studied. In each @entity0 's case, several parameters were analyzed based on the dose-volume histograms (DVH) of the IMRT, SA/PA-VMAT plans respectively. Also, each plan was delivered to a phantom for time comparison. RESULTS: The SA-VMAT plans showed the superior target dose coverage, although the minimum/mean/maximum doses to the target were similar. For the total and contralateral lungs, the higher V5/10, lower V20/30 and @entity2 ( @entity2 ) were observed in the SA/PA-VMAT plans (p < 0.05, respectively). The PA-VMAT technique improves the dose sparing (V20, V30 and @entity2 ) of the controlateral lung more notably, comparing to those parameters of the IMRT and SA-VMAT plans respectively. The delivered monitor units (MUs) and treatment times were reduced significantly with VMAT plans, especially PA-VMAT plans (for MUs: mean 458.3 vs. 439.2 vs. 435.7 MUs, p < 0.05 and for treatment time: mean 13.7 vs. 10.6 vs. 6.4 minutes, p < 0.01). CONCLUSIONS: The SA-VMAT technique achieves highly conformal dose distribution to the target. Comparing to the IMRT plans, the higher V5/10, lower V20/30 and @entity2 were observed in the total and contralateral lungs in the VMAT plans, especially in the PA-VMAT plans. The SA/PA-VMAT plans also reduced treatment time with more efficient dose delivering. But the clinical benefit of the VMAT technique for locally advanced @entity1 needs further investigations.

title: Planning analysis for locally advanced XXXX : dosimetric and efficiency comparisons between intensity-modulated radiotherapy (IMRT), single-arc/partial-arc volumetric modulated arc therapy (SA/PA-VMAT).

answer: @entity1


abstract: BACKGROUND: The development of collaterals in @entity2 has been described and these collaterals play an important role in the presentation of this disease. These collaterals are diagnostic and their use in management strategy has never been evaluated. This study aimed to investigate the indications, feasibility and necessity of invasive treatment for @entity0 with @entity2 and to determine whether such a strategy is necessary for optimal management. METHODS: Twenty-nine @entity0 who had been treated at our unit were enrolled in this study. Based on physical and biochemical examination, and hemodynamic compensation by collaterals, 18 @entity0 underwent radiological intervention (group A), while the other 11 had no invasive treatment (group B). The related hemodynamic parameters were acquired when percutaneous angiography was performed. RESULTS: In group A, all @entity0 underwent successfully inferior vena cava (IVC) balloon angioplasty with or without stenting. Four @entity0 also underwent hepatic vein angioplasty. In these @entity0 , the mean IVC pressure before and after treatment was statistically different (29.3+/-9.2 vs 15.1+/-4.6 mmHg, P<0.01). The mean IVC pressure was much lower in group B than in group A (12.9+/-2.4 vs 29.3+/-9.2 mmHg, P<0.01), but there was no difference from that of the @entity0 after radiological treatment (12.9+/-2.4 vs 15.1+/-4.6 mmHg, P>0.05). Median follow-up was 32.3 months (mean 21.3 months; range 3-61 months). In the course of follow-up, the @entity0 in group A survived with good systemic status except for @entity1 in one @entity0 who underwent re-canalization of the IVC. In group B, 10 @entity0 had good systemic status except one @entity0 who had a meso-caval shunt because of deterioration. CONCLUSIONS: The rationale of "early diagnosis and early treatment" is not suitable for all @entity0 with @entity2 . Satisfactory survival can be achieved in some @entity0 without invasive treatment, who are completely compensated by rich collaterals. Nonetheless, a positive treatment procedure should be performed if the @entity0 's situation worsens in the course of regular follow-up.

title: Necessity and indications of invasive treatment for XXXX .

answer: @entity2


abstract: BACKGROUND: Recent clinical trials using @entity9 + @entity0 cardiac stem cells (CSCs) demonstrated promising results in increasing cardiac function and improving quality of life. However, CSC efficiency is low, likely due to limited cell survival and engraftment after transplantation. The Rho-associated protein kinase (ROCK) inhibitor, @entity11 , significantly increased cell survival rate, adhesion, and migration in numerous types of cells, including stem cells, suggesting a common feature of the ROCK-mediated apoptotic pathway that may also exist in @entity0 CSCs. In this study, we examine the hypothesis that pretreatment of @entity0 CSCs with @entity11 protects cells from @entity7 ( @entity10 ) induced apoptosis. METHODS AND RESULTS: @entity9 + CSCs were cultured in CSC medium for 3-5 days followed by 48hr treatment with 0 to 10 M @entity11 alone, 0 to 1.0 M @entity10 alone, or @entity11 followed by @entity10 (48hrs). Cell viability, @entity2 , proliferation, morphology, migration, @entity3 activity, expression levels of apoptotic-related key proteins and @entity9 + were examined. Results showed that 48hr treatment with @entity11 alone did not result in great changes in @entity9 + expression, proliferation, @entity3 activity, or apoptosis; however cell viability was significantly increased and cell migration was promoted. These effects likely involve the ROCK/Actin pathways. In contrast, 48hr treatment with @entity10 alone dramatically increased @entity3 activity, resulting in cell death. Although @entity11 alone did not affect the expression levels of apoptotic-related key factors (p- @entity4 , @entity4 , @entity5 , @entity8 , @entity6 , cleaved @entity3 , and @entity3 ) under basal conditions, it significantly inhibited the @entity10 -induced increase in cleaved @entity3 and reduced cell death under @entity10 treatment. CONCLUSIONS: We conclude that preconditioning @entity0 CSCs with @entity11 significantly reduces @entity10 -induced cell death and possibly involves the cleaved @entity3 and ROCK/Actin pathways. The beneficial effects of @entity11 may be applied to stem cell-based therapy to increase cell survival rates after transplantation or to act as a cardiac protective agent for @entity10 -treated @entity1 @entity0 .

title: Rho-Associated Kinase Inhibitor ( @entity11 ) Attenuates @entity7 -Induced Apoptosis of XXXX Cardiac Stem Cells.

answer: @entity0


abstract: PURPOSE: Resistance to topoisomerase (TOP) 1 and 2 inhibitors is a potentially important reason for treatment failure, and may be related, in part, to a down-regulation of the specific TOP target. Investigators in our laboratories previously noted such a down-regulation of the target, along with a reciprocal up-regulation of the alternate TOP. Therefore, sequencing TOP inhibitors may provide a means for overcoming resistance to the TOP I and II inhibitors. Furthermore, point mutations in TOP I, which confer resistance to TOP I inhibitors, were associated with collateral sensitivity to @entity7 . EXPERIMENTAL DESIGN: A dose escalating Phase I trial of @entity10 (at doses of 0.75 to 1.0 mg/m(2)/day) on days 1 to 3 with @entity11 (70-80 mg/m(2)/day) and @entity7 (20-25 mg/m(2)/day) on days 8 to 10. The timing of the drug sequence was based on the prior Phase I pharmacokinetic and pharmacodynamic studies of @entity12 and @entity11 , and the level of the TOP targets in peripheral blood monocytes. RESULTS: Fifteen @entity0 (7 males and 8 females) received 40 courses of therapy across three dose levels. The median age was 56 (range, 39-77), and the median performance status was 1 (range, 0-2). The diagnoses included: @entity8 (7), @entity3 (2), @entity1 of unknown primary (2), and 1 each of @entity2 , @entity4 , @entity5 , and @entity6 . Level 1 ( @entity10 1.0 mg/m(2)/day; @entity11 80 mg/m(2)/day; and @entity7 25 mg/m(2)/day) produced severe and @entity9 in the first @entity0 treated, and the subsequent @entity0 were then entered onto a reduced dose level (cohort 2: @entity10 0.75 mg/m(2)/day; @entity11 70 mg/m(2)/day; and @entity7 20 mg/m(2)/day). Three of 6 @entity0 on cohort 2 experienced grade IV @entity9 >5 days, and a decision was then made to add filgrastim at 5 micro g/kg rather than additionally reduce the dosages (cohort 3). Eight @entity0 were then treated on cohort 3, and 1 of the 8 @entity0 experienced a grade 4 @entity9 . Thus, cohort level three was considered the recommended dose for Phase II studies. Twelve of the 15 @entity0 had disease assessable for response to therapy. Seven achieved stable disease for >/==" BORDER="0">2 months, whereas 5 showed continued progression of their disease. CONCLUSIONS: These data show that sequencing TOP 1 and 2 inhibitors is feasible, and @entity10 0.75 mg/m(2)/day days 1-3; @entity11 70 mg/m(2)/day days 8-10; and @entity7 20 mg/m(2)/day days 8-10 with filgrastim at 5 micro g/kg is an appropriate dose and schedule to test the concept of modulating TOP levels by sequencing the administration of the respective TOP inhibitors.

title: Sequencing @entity10 and @entity11 plus XXXX to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.

answer: @entity7


abstract: UNASSIGNED: @entity0 are surrounded and infiltrated by a variety of stromal cell types, including fibroblasts, immune cells, and vascular endothelial cells, which interact with malignant cells to generate the @entity0 microenvironment (TME). This complex environment is thought to be regulated by the @entity0 in order to promote its survival and progression and thus constitutes a potential target for @entity0 therapy. However, intercellular communication within the microenvironment is not yet well understood. The current study investigates the mechanism by which @entity0 and immune cells communicate using an in vitro coculture model. It is demonstrated that @entity3 , a proinflammatory cytokine, secreted by immune cells promotes @entity1 cell invasiveness. In addition, in the presence of @entity3 , the @entity0 cells were able to secrete circulating miRNAs @entity4 and @entity5 to further induce immune cell @entity3 production. Activated immune cells were also found to release @entity4 into the TME. Taken together, these mechanistic findings provide a better understanding of intercellular communication between immune and @entity0 cells in the TME and offer insight into some of the key players that mediate this cross-talk. IMPLICATIONS: This study demonstrates that @entity0 and immune cells communicate via @entity3 and circulating miRNAs to sustain chronic @entity2 and promote prometastatic @entity0 cell behavior. In addition, critical players are identified that mediate intercellular communication in the TME and suggest possible therapeutic approaches that target the microenvironment. Mol Cancer Res; 13(11); 1-7.   2015 AACR.

title: XXXX Mediates Immune and @entity1 Cell Cross-talk via @entity4 and @entity5 .

answer: @entity3


abstract: OBJECTIVE: To systematically review the efficacy of multicomponent treatment of @entity1 ( @entity1 ). METHODS: We screened Medline, PsychINFO, Scopus, and the Cochrane Library (through December 2007), as well as reference sections of original studies, reviews, and evidence-based guidelines. Randomized controlled trials (RCTs) on the multicomponent treatment (at least 1 educational or other psychological therapy with at least 1 exercise therapy) of @entity1 were analyzed. RESULTS: We included 9 (of 14) RCTs with 1,119 subjects (median treatment time 24 hours) in the meta-analysis. Effects were summarized using standardized mean differences (SMDs) or @entity3 ( @entity3 ). There was strong evidence that multicomponent treatment reduces @entity0 ( @entity5 -0.37; 95% confidence interval [95% CI] -0.62, -0.13), fatigue (WMD -0.85; 95% CI -1.50, -0.20), @entity2 ( @entity5 -0.67; 95% CI -1.08, -0.26), and limitations to health-related quality of life (HRQOL) ( @entity5 -0.59; 95% CI -0.90, -0.27) and improves self-efficacy @entity0 ( @entity5 0.54; 95% CI 0.26, 0.82) and physical fitness ( @entity5 0.30; 95% CI 0.02, 0.57) at posttreatment. There was no evidence of its efficacy on @entity4 , @entity2 , HRQOL, or self-efficacy @entity0 in the long term. There was strong evidence that positive effects on physical fitness ( @entity5 0.30; 95% CI 0.09, 0.51) can be maintained in the long term (median followup 7 months). CONCLUSIONS: There is strong evidence that multicomponent treatment has beneficial short-term effects on the key symptoms of @entity1 . Strategies to maintain the benefits of multicomponent treatment in the long term need to be developed.

title: Efficacy of multicomponent treatment in XXXX : a meta-analysis of randomized controlled clinical trials.

answer: @entity1


abstract: BACKGROUND:: @entity3 with @entity11 and systemic symptoms is a severe adverse @entity3 , with a reported mortality of 10%. Long-term outcomes involve @entity8 and @entity7 in some populations. OBJECTIVE:: To evaluate the clinical prognosis of @entity0 with @entity3 with @entity11 and systemic symptoms. METHODS:: We conducted a retrospective review at a referral hospital in Mexico City in a period of 22 years (1992-2013), looking up for records with diagnosis of DRESS according to RegiSCAR criteria. Clinical characteristics, organ failures, culprit drugs, treatment, and short and long-term sequelae were analyzed. RESULTS:: We found 11 @entity0 with diagnosis of @entity3 with @entity11 and @entity1 , 7 female and 4 male, with a median age of 22 years-old; 9 had maculopapular rash and 2 were erythrodermic. Affected organs were liver (8/11), kidney (6/11) and @entity9 (8/11). The most common culprit drugs were antiepileptic (63%). Systemic @entity5 were given to 8 @entity0 , being @entity12 (1/8) and @entity2 (2/8) the adverse events of this therapy. Long-term sequelae were 1 @entity0 with @entity4 , 1 @entity0 with @entity6 ; and 2 @entity0 developed @entity7 (one @entity10 and another one with @entity10 and @entity13 ). Study limitations: The retrospective nature of the study and the limited number of @entity0 with @entity3 with @entity11 and systemic symptoms. CONCLUSIONS:: @entity3 with @entity11 and @entity1 has been linked to the development of chronic organ failure. We found two young @entity0 who developed @entity7 in the short term. @entity0 with @entity3 with @entity11 and systemic symptoms should have a long-term monitoring for signs or symptoms suggestive of an @entity7 .

title: @entity3 with @entity11 and systemic symptoms (DRESS) and its relation with XXXX in a reference center in Mexico.

answer: @entity7


abstract: BACKGROUND/AIMS: The objective of this study was to evaluate the efficacy and safety of landiolol hydrochloride, a newly developed ultra-short-acting b1-selective blocker, for @entity1 after esophagectomy. METHODOLOGY: In total 231 @entity0 underwent transthoracic esophagectomy at the Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine from 2007 to 2012. Twenty-four @entity0 who were treated with either landiolol hydrochloride (n = 11) or conventional agents (combination of @entity2 channel blocker and digitalis preparation; control group, n = 13) for @entity1 after transthoracic esophagectomy were retrospectively analyzed. @entity4 was defined as a heart rate of >120 bpm or @entity5 . Hemodynamic changes, conversion rates, and adverse events were evaluated. RESULTS: The reduction in the heart rate at 1 h after medication was seen significantly more frequent in the @entity7 group than in the control group. The time to conversion to sinus rhythm was also significantly shorter in the @entity7 group. There were no significant differences between the two groups in blood pressure either before or after the medication. One @entity0 in the @entity7 group showed @entity3 and @entity6 , without serious consequences. CONCLUSIONS: Landiolol hydrochloride can be effectively and safely used in @entity0 who develop @entity4 after esophagectomy.

title: Effect of landiolol hydrochloride on XXXX after esophagectomy.

answer: @entity4


abstract: PURPOSE: @entity9 is a @entity7 -polymer conjugate prepared by linking @entity7 ( @entity5 ) to a hydrophilic, cyclodextrin-based, linear polymer through @entity8 bonds. In previous studies, these polymer conjugates with high molecular weights (ca 90 kDa) have shown significant antitumor effects against @entity0 @entity4 xenografts. The pharmacokinetics of @entity9 in plasma of @entity3 and its biodistribution in @entity2 bearing @entity0 LS174T @entity4 is reported here. METHODS: @entity3 were injected intravenously with three different doses of @entity9 . Serial plasma samples were analyzed for polymer-bound and unconjugated @entity5 by high-performance liquid chromatography (HPLC). Concentration vs time data were modeled using non-compartmentalized methods and compared to @entity5 alone injected intravenously at an equivalent dose. Tumor-bearing @entity2 were injected intravenously with @entity9 and intraperitoneally with @entity5 alone, and sacrificed after 24 and 48 h, and serum, heart, liver, spleen, lungs and @entity1 collected. Tissue samples were extracted and analyzed for polymer-bound and unconjugated @entity5 by HPLC. RESULTS: Plasma concentrations and the area under the curve for polymer-bound @entity5 are approximately 100-fold higher than those of unconjugated @entity5 or @entity5 alone, injected intravenously at an equivalent dose. The plasma half-life of @entity9 ranges from 17 -20 h and is significantly greater than that of @entity5 alone (1.3 h). When @entity5 is conjugated to polymer, the biodistribution pattern of @entity5 is different from that taken alone. At 24 h post injection, the total @entity5 per gram of tissue is the highest in @entity1 tissue when compared to all other tissues tested. Tumor concentrations of active @entity5 released from the conjugate are more than 160-fold higher when administered as a polymer conjugate rather than as @entity5 alone. CONCLUSIONS: The studies presented here indicate that intravenous administration of @entity9 , a cyclodextrin based polymer- @entity5 conjugate, gives prolonged plasma half-life and enhanced distribution to @entity1 tissue when compared to @entity5 alone. The data also show that active @entity5 is released from the conjugate within the @entity1 for an extended period of time. These effects likely play a significant role in the enhanced antitumor activity of @entity9 when compared to @entity5 alone or @entity6 .

title: Pharmacokinetics and biodistribution of the @entity7 -polymer conjugate @entity9 in @entity3 and XXXX -bearing @entity2 .

answer: @entity1


abstract: The effects of @entity1 intercalation on chromatin structure were monitored by viscometry and analysis of histone dissociation. Investigation of the @entity0 concentration dependence of chromatin viscosity showed that the reduced viscosity (etared) was very low up to 0.4 M @entity0 and increased gradually when the salt concentration was raised further. In chromatin intercalated by @entity1 , etared was not significantly different at low salt concentrations (up to 0.2 M @entity0 ). However, when the salt concentration was raised further, the viscosity response curve increased sharply to reach viscosities about 4-5 times higher than those for nonintercalated chromatin. The increase in viscosity was proportional to the increase in fluorescence intensity, when the ratio of @entity1 to DNA mucleotide was raised. The transition of intercalated chromatin into the relaxed form was reversible, dependent on the nature of the electrolyte and cooperative, as indicated by the small increase in salt concentration required to obtain chromatin relaxation. Investigation of the @entity0 concentration dependence of histone dissociation revealed that total histones and each individual histone fraction were released from intercalated chromatin at much reduced @entity0 concentrations. The midpoints of the dissociation curves of the individual histones ranged from 0.30 to 0.45 M @entity0 and fell within the same range where the drastic viscosity change occurred. These results indicate that intercalation of @entity1 labilizes chromatin structure to relaxation by moderately elevated salt concentrations. It is suggested that the labilization is caused by changes in the DNA helix conformation due to dye intercalation decreasing the stability of histone-DNA interactions.

title: Relaxation of chromatin structure by XXXX binding: determined by viscometry and histone dissociation studies.

answer: @entity1


abstract: OBJECTIVE: To access the production of a novel uterine luminal fluid 250 kD protein (ULF-250) during the various phases of the estrous cycle in relation to @entity2 concentration, and to validate that the production and secretion of ULF-250 are regulated by @entity1 and @entity3 . METHODS: An immunohistochemical method was used to localize ULF-250 in @entity0 uteri during each phase of the estrous cycle, and in uteri of ovariectomized @entity0 treated with @entity1 and @entity3 . RESULTS: Positive immunostaining of ULF-250 occurred in the epithelial cells of the uterus at all phases of the estrous cycle; whereas the stroma was immunonegative. During the proestrus phase of the cycle, the glandular epithelial cells and glandular luminal content were stained strongly. During the estrus phase of the cycle, intense staining occurred in the glandular and uterine luminal epithelial cells, including the luminal content of the glands. In the metestrus phase of the cycle, only uterine epithelial cells were stained; during the diestrus phase, intense staining of the secreted contents of the uterine cavity and the glandular lumen occurred. The distribution of ULF-250 in the uteri of ovariectomized female @entity0 treated with @entity1 alone and @entity1 plus @entity3 were examined. In both groups, intense staining of the glandular luminal epithelial cells of the uterine endometrium occurred; in the @entity1 -treated animals, only the luminal contents were stained. The present findings suggest that @entity3 inhibits the secretion of ULF-250 that is stimulated by @entity1 . CONCLUSIONS: ULF-250 is produced by the glandular and luminal epithelial cells of the uterine endometrium and fluctuates with the phases of the estrous cycle. Its production is stimulated by @entity1 and its secretion is regulated by @entity3 .

title: Immunolocalization of uterine luminal fluid protein (ULF-250) in XXXX uterus.

answer: @entity0


abstract: BACKGROUND: @entity3 plays a crucial role in the progression of @entity0 ( @entity0 ) and a prognostic role of in @entity0 @entity1 has been widely reported. However, controversy still remains. MATERIALS AND METHODS: Identical search strategies were used to search relevant literature in electronic databases updated to July 1, 2014. Individual hazard ratios (HRs) and 95% confidence intervals (CIs) were extracted and pooled HRs with 95%CIs were used to evaluate the strength of association between positive @entity3 expression in different subcellular locations and survival results of @entity0 @entity1 . Subgroup and meta-regression analyses were performed to explore heterogeneity. Funnel plots of Begg's and Egger's linear regression test were used to investigate publication bias. Heterogeneity and sensitivity were also assessed. All the work was completed using STATA. RESULTS: A total of 2,204 @entity1 from 12 evaluative studies were finally included. Pooled HRs and 95%CIs suggested that @entity3 expression in cytoplasm/nucleus had an unfavorable impact on both @entity2 ( @entity2 ) (HR: 1.93, 95%CI: 1.40-2.65) and disease free survival (DFS)/ @entity2 ( @entity2 ) (HR: 1.60, 95%CI: 1.20-2.13) in @entity0 @entity1 . However, here was no significant association between @entity3 expression in the membranes with @entity2 (HR: 0.65, 95%CI: 0.42-1.02) or DFS/ @entity2 (HR: 0.66, 95%CI: 0.38-1.13). Publication bias was absent in all of the four outcomes. Sensitivity analysis revealed that the results of this meta-analysis were robust. CONCLUSIONS: Positive @entity3 expression in cytoplasm/nucleus rather than in membrane is a significant prognostic factor in @entity1 with @entity0 who have been surgically treated.

title: Prognostic Value of XXXX Expression in @entity0 @entity1 : a Meta-analysis.

answer: @entity3


abstract: UNASSIGNED: This study which is a retrospective chart review aims to characterize the comorbidities associated with adult @entity1 and evaluate the relationship of these with @entity1 grade, length, surgical interventions, and surgical intervals. @entity0 ' demographics, medical and surgical comorbidities, grade of @entity1 , quantity and degree of balloon dilations, dilation intervals, open airway procedures, and tracheotomy status were recorded from 2002 to 2012, at a tertiary voice and airway center. Surgical outcomes were evaluated in relation to @entity0 comorbidities, @entity1 quality, and surgical procedures. A total of 101 @entity0 with @entity1 were examined with female @entity0 comprising 71  % of the population. Seventeen @entity0 (16.8  %) had idiopathic @entity1 . Number of balloon dilations ranged from 0 to 24 (mean  =  3.3). The average time between dilations was 38.4  weeks (range  =  1.14-215.8  weeks). The @entity0 with idiopathic @entity1 were found to have a lower grade (p  =  0.0066). Fifty-two @entity0 (51.5  %) received a tracheotomy at one point during their management. The 14 @entity0 (13.9  %) who remained tracheotomy dependent had a body mass index (BMI) of >30. No statistically significant correlation was found when the @entity0 ' age, BMI and comorbidites were compared with the grade of @entity1 , number of balloon dilatations needed and other surgical interventions. On the other hand, interval in between surgeries was found to be longer in @entity0 without an intubation history, and in idiopathic @entity2 (p  =  0.004, p  =  0.015, respectively). There was no significant relationship between surgical interval and gender, BMI, length of @entity1 , grade (p  =  0.059, p  =  0.47, p  =  0.97, p  =  0.36, respectively). Airway @entity1 in adults is complicated by the presence of multiple comorbidities. Better understanding of the etiology could aid in the prevention of the injury before it forms.

title: Comorbidities and factors associated with endoscopic surgical outcomes in adult XXXX .

answer: @entity1


abstract: 1. Tumour @entity1 factor-alpha ( @entity9 ) is a cytokine that is implicated in the pathogenesis of ischaemic states and @entity5 . We tested the hypothesis that the vasoprotective effects of the @entity14 may be mediated in vivo by inhibition of the formation of @entity9 . 2. Anaesthetized @entity0 , subjected to total occlusion of the superior mesenteric artery and the coeliac trunk for 45 min developed a severe @entity8 state resulting in a fatal outcome within 75-90 min after the release of occlusion. Sham-operated animals were used as controls. 3. @entity3 ( @entity3 ) shocked @entity0 had a marked @entity4 , enhanced levels of @entity9 in serum and macrophages, @entity7 and increased ileal leukocyte accumulation, studied by means of @entity10 activity ( @entity10 ). Furthermore, aortae from @entity3 @entity0 showed a marked hyporeactivity to @entity13 (PE, 1 nM-10 microM), reduced responsiveness to @entity6 ( @entity12 , 10 nM-10 microM) and an increased staining for @entity11 ( @entity11 ). 4. In vivo administration of 17 beta @entity2 (500 micrograms kg-1, i.m., three hours before the induction of @entity3 ) increased survival rate (100%, 4 h after @entity3 ), enhanced mean arterial blood pressure; reduced serum @entity9 (25 +/- 5 u ml-1 vs 379 +/- 16 u ml-1), ameliorated leukopaenia and reduced ileal @entity10 (0.7 +/- 0.02 u 10(-3) g-1 tissue vs 4.2 +/- 0.4 u 10(-3) g-1 tissue). Furthermore aortae from @entity3 @entity0 treated with 17 beta @entity2 exhibited a greater contractile response to @entity13 , improved responsiveness to @entity12 and a blunted staining of @entity11 . Finally 17 beta @entity2 , added in vitro to peritoneal macrophages collected from untreated @entity3 @entity0 , significantly reduced @entity9 production. 5. Our results suggest that inhibition of @entity9 in vivo may explain, at least in part, the vasoprotective effects of @entity14 .

title: The involvement of tumour @entity1 factor-alpha in the protective effects of 17 beta XXXX in splanchnic ischaemia-reperfusion injury.

answer: @entity2


abstract: UNASSIGNED: Objective. To investigate the correlation of @entity7 with @entity3 . Methods. Coronary angiography confirmed CAD in 241 @entity0 (62 received CABG) and non-CAD in 121 (55 received valve replacement). Results. Serum levels of LDL-C, @entity5 , @entity2 , @entity4 , and leptin in CAD @entity0 were significantly higher than those in non-CAD @entity0 (P < 0.05), but @entity6 and @entity7 were lower (P < 0.05). Serum levels of @entity7 and @entity6 were negatively related to BMI, HOMA-IR, @entity2 , @entity4 , and leptin but positively to HDL-C (P < 0.05) in CAD @entity0 . After adjustment of @entity6 , @entity7 was still related to the above parameters. Serum @entity7 was a protective factor of CAD (P < 0.05). When compared with non-CAD @entity0 , leptin mRNA expression increased dramatically, while @entity7 mRNA expression reduced markedly in epicardial adipose tissue of CAD @entity0 (P < 0.05). The leptin expression and macrophage count in CAD group were significantly higher than in non-CAD group, but CAD @entity0 had a markedly lower @entity7 expression (P < 0.05). Conclusions. Circulating and coronary @entity7 plays an important role in the @entity1 and @entity3 of CAD patients. Serum @entity7 is an independent protective factor of CAD.

title: Associations of C1q/TNF-Related Protein-9 Levels in Serum and Epicardial Adipose Tissue with XXXX in @entity0 .

answer: @entity3


abstract: UNASSIGNED: @entity3 ( @entity4 ) plays a fundamental role in plant defense signaling network. Recently, we have established the involvement of @entity4 with @entity2 (ET) to combat environmental stress. However, the mechanism of @entity4 -ET interplay still remains unexplored. Here, we demonstrate that @entity4 induces ET biosynthesis by modulating the transcriptional and post-trancriptional regulations of its key enzymes, ACC synthase (ACS) and @entity8 (ACO). Transgenic @entity1 plants with enhanced @entity4 content (AtECS) exhibited remarkable up-regulation of @entity5 , @entity6 and @entity9 at transcript as well as protein levels while they were down-regulated in the @entity4 depleted pad2-1 mutant. We further observed that @entity4 induced @entity5 and @entity6 transcription in a @entity7 dependent manner while @entity9 transcription remained unaffected. On the other hand, the mRNA stability for @entity9 was found to be increased by @entity4 which explains our above observations. In addition, we also identified the @entity9 protein to be a subject for S-glutathionylation which is consistent with our in silico data. However, S-glutathionylation of @entity5 and @entity6 proteins was not detected. Further, the AtECS plants exhibited resistance to @entity0 and salt stress while the pad2-1 mutant was sensitive. Exogenously applied @entity4 could improve stress tolerance in wild-type plants but not in the ET signaling mutant, ein2-1, indicating that @entity4 mediated resistance to these stresses occurs via an ET mediated pathway. Together, our investigation reveals a dual-level regulation of ET biosynthesis by @entity4 during stress.

title: @entity3 regulates ACC synthase transcription via XXXX and @entity8 by modulating mRNA stability to induce @entity2 synthesis during stress.

answer: @entity7


abstract: PURPOSE: The aim of this study was to evaluate the efficacy of @entity4 and success of treatment in particular etiological causes in @entity1 lasting more than 3 months. MATERIAL AND METHODS: A total of 141 @entity0 between 27 and 78 years old without any cardiac compromise, despite controversial, which precludes @entity4 (Viagra) treatment, were included in this study. All @entity0 had only International Index of Erectile Capacity Form (IIEF) for pre-treatment evaluation and 50 mg @entity4 was started. @entity0 were assessed monthly for 6 months thereafter. Erectile capacity changes were questioned by IIEF on each follow-up and 100 mg @entity4 was given in @entity0 without a response and monthly follow-up was scheduled. All @entity0 had SMA-12, hormonal analyses and penile colour Doppler ultrasonography during the treatment course. The difference between IIEF score of each @entity0 was displayed by Paired-t test and p-values less than 0.05 was applied as significant. RESULTS: The average beginning IIEF score of 141 @entity0 was 11.80 +/- 0.47 [6-22], and increased to 20.70 +/- 0.62 [6-30] after a month of 50 mg @entity4 treatment. The mean increase was 75.4% and found to be significant (p = 0.000, p < 0.05). The average IIEF scores were recorded as 22.57 +/- 0.69 after 3, and 22.12 +/- 0.24 after 6 months. There was no difference between these values and 2nd month controls (P3 month = 0.5675, P6 month = 0.6138, p > 0.05). A positive response was recorded in 102 @entity0 (72.3%) and 39 (27.7%) @entity0 were unresponsive. Doubled doses of @entity4 (100 mg) was effective in additional 17 @entity0 . After overall treatment, 119 (84.4%) @entity0 had benefit from @entity4 . Penile Doppler ultrasonography displayed @entity5 in 79 (56.03%), @entity3 in 14 (9.93%), mixt vascular pathology in 14 (9.93%) @entity0 . Normal ultrasonographic findings in 32 @entity0 (22.7%) were classified as @entity2 . Among the organic causes, @entity4 was found to be most effective in @entity5 group. CONCLUSION: @entity4 is a successful management modality in @entity1 with minimal pre-treatment evaluation. As far as etiological causes concerned, @entity4 was found to be most effective in @entity5 group and psychogenic group. The efficacy of @entity4 treatment has not been changed with the treatment time, since IIEF scores were stable during follow-up controls.

title: The efficacy of XXXX in different etiologies of @entity1 .

answer: @entity4


abstract: OBJECTIVE: To study the metabolism of @entity3 (BK) after a single passage through the coronary bed in isolated Langendorff @entity0 hearts. METHODS: BK was infused into the aortic flow line to obtain a final concentration of 10 nM, and the coronary, effluent was collected to quantify BK and des-Arg9-BK by competitive enzyme immunoassay. The nature of immunoreactive material was confirmed by immunograms after @entity1 . The experiments were performed with hearts perfused at either one of the following coronary flow rates: 1, 5 or 10 ml/min. RESULTS: BK recovery without inhibitors was 86.3 +/- 2.9, 60.8 +/- 6.3, and 29.6 +/- 6.8% at 10, 5, and 1 ml/min, respectively. The Vmax/Km ratios at these coronary flow rates were 2.19 +/- 0.72, 4.81 +/- 0.64, and 2.59 +/- 0.33 min-1 g-1), respectively. The @entity2 ( @entity2 ) inhibitor, enalaprilat (130 nM), reduced BK degradation at all flow rates. Inhibition of neutral endopeptidase with retrothiorphan (25 nM) had no effect on BK degradation. However, the combined treatment with @entity4 and @entity5 reduced BK degradation to lower values than enalaprilat alone. The effect of enzyme inhibitors on BK recovery was inversely related to coronary flow: inhibiting BK degradation markedly increased BK recovery at 1 ml/min, but had no effect at 10 ml/min. The kininase I metabolite of BK, des-Arg9-BK, could not be detected under these experimental conditions. CONCLUSIONS: @entity2 is the major enzyme responsible for BK degradation during a single passage through the coronary bed. Neutral endopeptidase contributes to BK degradation only when @entity2 activity is impaired. The effect of enzyme inhibitors on the coronary concentration of BK is highly dependent on coronary flow rate.

title: Metabolism of XXXX by the @entity0 coronary vascular bed.

answer: @entity3


abstract: OBJECTIVE: To estimate direct and indirect contact rates on livestock facilities and distance traveled between herd contacts. SAMPLE POPULATION: 320 beef, dairy, @entity2 , @entity1 , and @entity3 herds, 7 artificial insemination technicians, 6 hoof trimmers, 15 veterinarians, 4 sales yard owners, and 7 managers of livestock-related companies within a 3-county region of California. PROCEDURE: A questionnaire was mailed to livestock producers, and personal and telephone interviews were conducted with individuals. RESULTS: Mean monthly direct contact rates were 2.6, 1.6, and 2.0 for dairies with < 1,000, 1,000 to 1,999, and > or = 2,000 @entity0 , respectively. Mean indirect contact rates on dairies ranged from 234 to 743 contacts/mo and increased by 1 contact/mo as herd size increased by 4.3. Mean direct monthly contact rate for beef herds was 0.4. Distance traveled by personnel and vehicles during a 3-day period ranged from 58.4 to 210.4 km. Of livestock arriving at sales yards, 7% (500/7,072) came from > or = 60 km away, and of those sold, 32% (1,180/3,721) were destined for a location > or = 60 km away. Fifty-five percent (16/29) of owners of large beef herds observed deer or @entity4 within 150 m of livestock at least once per month. CONCLUSIONS AND CLINICAL RELEVANCE: Direct and indirect contacts occur on livestock facilities located over a wide geographic area and at a higher frequency on larger facilities. Knowledge of contact rates may be useful for planning biosecurity programs at the herd, state, and national levels and for modeling transmission potential for @entity5 virus.

title: Direct and indirect contact rates among beef, dairy, XXXX , @entity1 , and @entity3 herds in three California counties, with reference to control of potential @entity5 transmission.

answer: @entity2


abstract: UNASSIGNED: Polymeric microspheres may serve as microcarrier matrices, for the expansion of anchorage-dependent stem cells. They require surface properties that both promote initial cell adhesion and the subsequent spreading of cells, which is a prerequisite for successful expansion. When implemented in a three-dimensional culture environment, under @entity3 , their suspension under low shear rates depends on the microcarriers having a modest negative buoyancy, with a density of 1.02-1.05 g/cm(3). Bioresorbable @entity4 ( @entity4 ), with a density of 1.14 g/cm(3), requires a reduction in volumetric density, for the microspheres to achieve high cell viability and yields. Uniform-sized droplets, from solutions of @entity4 dissolved in @entity1 ( @entity5 ), were generated by a coaxial microfluidic geometry. Subsequent exposure to @entity2 rapidly extracted @entity5 solvent, solidifying the droplets and yielding monodisperse microspheres with a porous structure, which was demonstrated to have tunable porosity and a core-shell configuration. The variation of process parameters, including the molecular weight of @entity4 , its concentration in @entity5 , and the @entity2 concentration, served to effectively alter the diffusion flux between @entity2 and @entity5 , resulting in a broad spectrum of volumetric densities of 1.04-1.11 g/cm(3). The solidified microspheres are generally covered by a smooth thin skin, which provides a uniform cell culture surface and masks their internal porous structure. When coated with cationic polyelectrolyte and extracellular matrix protein, monodisperse microspheres with a diameter of approximately 150   m and densities ranging from 1.05-1.11 g/cm(3), are capable of supporting the expansion of @entity0 mesenchymal stem cells (hMSCs). Validation of hMSC expansion was carried out with positive control of commercial Cytodex 3 microcarriers and negative control of uncoated low-density @entity4 microcarriers. Static culture conditions generated more than 70% cell attachment and similar yields of 6-fold cell expansion on all coated microcarriers, with poor cell attachment and growth on the negative control. Under @entity3 , coated porous microspheres, with a low density of 1.05 g/cm(3), achieved robust cell attachment and resulted in high cell yields of 9-fold cell expansion, comparable to those generated by commercial Cytodex 3 microcarriers.

title: Tunable Volumetric Density and Porous Structure of Spherical Poly-  -caprolactone Microcarriers, as Applied in XXXX Mesenchymal Stem Cell Expansion.

answer: @entity0


abstract: The two-electrode voltage-clamp technique was used to evaluate the effect of protein kinase C (PKC) activation on ion current flow in @entity3 oocytes injected with cRNA coding for the @entity0 vanilloid receptor ( @entity8 ). In the presence of 30 nM @entity6 ( @entity7 ), current evoked by an effective concentration (EC(30)) of @entity4 (CAP) was potentiated by 638+/-117% (n=8). PDBu exhibited an EC(50) of about 17+/-3 nM for this effect (n=8). Potentiation was not observed when @entity8 expressing oocytes were exposed to both 30 nM PDBu and 1 microM @entity2 . In the presence of 300 nM PDBu, the EC(50) for CAP shifted from 899+/-78 to 139+/-2 1 nM (n=11 and 5, respectively). In the presence of 30 nM PDBu, the maximal current amplitude evoked by application of CAP increased by 86+/-21% (n=10), in a @entity2 sensitive manner. Application of 1 microM PDBu alone elicited a @entity5 sensitive current within 3 min of exposure. This effect was observed in the absence of previous exposure of the oocyte to CAP and was abolished in the presence of 1 microM @entity2 . No current was elicited during a 10 min application of 300 nM PDBu, the longest interval assessed. Prior to 30 nM PDBu exposure, no current was evoked at temperature ramps from room temperature (22-23 degrees C) up to 37 degrees C at pH 6.8, 7.0, or 7.4. Following PDBu treatment, @entity8 mediated current was evoked at 26 degrees C at pH 7.0. Likewise, following 30 nM PDBu treatment, current was evoked by application of pH 6.8 alone and a further increase in current amplitude was evoked by heat at 24 degrees C in a @entity2 sensitive manner. These data provide direct evidence that PKC activation can increase @entity8 current evoked by candidate physiological activators, pH and heat. This observation provides an empirical foundation for explaining some types of @entity1 in terms of PKC activation, small decreases in tissue pH levels, and small increases in skin temperature, all of which can accompany inflammatory conditions.

title: Activation of protein kinase C sensitizes @entity0 @entity8 to XXXX and to moderate decreases in pH at physiological temperatures in @entity3 oocytes.

answer: @entity4


abstract: BACKGROUND: Several studies have identified occupational exposure to extremely low-frequency electromagnetic fields (EMF) as a potential risk factor for @entity1 , but the evidence is contradictory and inconclusive. METHODS: We conducted a cohort study to explore these associations. We studied all economically active individuals in the Swedish 1980 census (4,812,646 subjects), and followed them for @entity1 mortality from 1981 through 1995. Information about occupation was available for 1970 and 1980. A job-exposure matrix based on magnetic field measurements was used to assess EMF exposure. RESULTS: An increased risk of @entity2 mortality was observed among @entity0 exposed both in 1970 and 1980 (relative risk = 2.3; 95% confidence interval = 1.6-3.3 for exposure >/=0.5 microT). The associations were most pronounced for early-onset @entity2 mortality or with follow-up limited to 10 years after the last known occupation. @entity3 was not associated with EMF exposure, but the risk estimate with "electrical and electronics work" was 1.4 (95% confidence interval = 1.1-1.9). CONCLUSIONS: Our study gives some support to the hypothesis that EMF exposure increases the risk of early-onset @entity2 , and suggests that magnetic field exposure may represent a late-acting influence in the disease process. @entity4 is an unlikely explanation for the increased risk of @entity3 in "electrical and electronics work" in this study.

title: Occupational magnetic field exposure and XXXX .

answer: @entity1


abstract: OBJECTIVE: Many @entity0 with @entity4 ( @entity9 ). Because open repair is associated with a high morbidity and mortality, hybrid approaches to @entity9 repair are emerging. In this study, we evaluated the midterm outcomes and aortic remodeling of a hybrid technique that combines proximal @entity3 repair (TEVAR), followed by staged distal open thoracoabdominal repair for @entity0 with Crawford extent I or II TAAAs secondary to chronic @entity8 . METHODS: We identified 19 @entity0 with Crawford extent I (n  = 1) or extent II (n  = 18) TAAAs secondary to chronic @entity8 who underwent a staged hybrid repair from 2007 to 2014 at our institution. Nine @entity0 had previous open ascending aortic surgery for type I @entity8 . Stage 1 TEVAR was performed via percutaneous (n  = 8), femoral cutdown (n  = 8), or iliac exposure (n  = 3). The left subclavian artery was covered in nine @entity0 and revascularized in eight @entity0 using carotid-subclavian bypass (n  = 7) or laser fenestration (n  = 1). Stage 2 open repair was performed a median of 18  weeks later with partial cardiopulmonary bypass via left femoral arterial and venous cannulation for visceral and lower body perfusion. The open thoracoabdominal graft was anastomosed proximally in an end to end fashion with the endograft. We then assessed surgical morbidity and mortality, midterm survival, and freedom from reintervention. Aortic remodeling was measured and change in maximum aortic and false lumen diameter at last follow-up (median, 3  years) from baseline was assessed. RESULTS: There were no deaths, @entity1 , or @entity2 in this cohort. After stage 1 TEVAR, three @entity0 required repeat intervention for endoleak (type IA, n  = 1; type IB, n  = 1; type II, n  = 1) before open repair. After stage 2 open repair, there was a single delayed permanent @entity6 2  weeks after discharge. At a median 3-year follow-up (range, 6 months-6.2  years), there were no deaths, neurologic events, @entity7 , or @entity9 reinterventions. Complete false lumen @entity5 occurred in 100% of the @entity0 , with maximum false lumen diameter decreasing from 34.3     15.3  mm to 13.2     12.0  mm  (P  < .01) and total aortic diameter decreasing from 60.2     9.0  mm to 49.4     9.6  mm  (P  <  .01). CONCLUSIONS: Staged hybrid @entity9 repair, using a combination of proximal TEVAR with open distal repair, can be performed using established endovascular skills and technology coupled with traditional open aortic surgical techniques, with low surgical morbidity and mortality. In the midterm, staged hybrid @entity9 repair was associated favorable survival, aortic remodeling, and freedom from reintervention.

title: Staged hybrid repair of extensive XXXX secondary to chronic @entity8 .

answer: @entity9


abstract: Several Asian countries are implementing nationwide @entity0 screening programs. Assessment of the effectiveness of these programs is critical to their success as this is the only way to ensure that the benefits of screening outweigh the harms. In this paper we focus on @entity1 ( @entity1 ) screening to illustrate the principles of screening program assessment. The International Agency for Research on @entity0 (IARC) has defined organized screening, distinguishing it from opportunistic screening. The key advantage of organized screening is that it provides greater protection against the possible harms of screening. Since screening is a process, not simply a test, the effectiveness of a program depends on the quality of each step in the @entity0 screening process. The evaluation of long-term screening program outcomes ( @entity1 incidence and mortality) will not be observable for many years, given the time it takes to plan, pilot and implement a program. However, early performance indicators of the impact of screening should be monitored to give an early indication whether the program is on track. The European Union (EU) has recommended a minimum dataset to be collected and reported regularly by a screening program. Using information from these data tables, early performance indicators can be generated (e.g., participation rate, proportion of screen-detected @entity0 that are early-stage). Subsequently, modeling the natural history of the disease can be very helpful to estimate long-term outcomes, making use of these directly measured early performance indicators. Modeling can also be used to estimate the cost-effectiveness of a screening program and the potential impact of changes in policy, as illustrated by its recent use in the Netherlands to change the definition of a positive fecal immunochemical test (FIT) for the @entity1 screening program. Programs should consider modeling as an important component of screening program evaluation.

title: Assessment of a XXXX screening program.

answer: @entity0


abstract: AIM: To compare the clinical acceptability of two dose regimens of micronized purified @entity6 fraction (MPFF): a single 1000 mg tablet once daily versus 500 mg twice daily in @entity0 suffering from @entity2 ( @entity2 ). METHODS: In an international, randomized, double-blind, parallel-group study, 174 @entity0 (Clinical Etiological Anatomic Pathophysiologic [CEAP] class C0s to C4) were randomized to MPFF 1000 mg once daily or MPFF 500 mg twice daily for 8 weeks. Adverse events were recorded in @entity0 -kept diaries (weeks 0, 2, 4, 8) and leg @entity3 was assessed using a visual analog scale (VAS). RESULTS: No serious adverse events occurred. A total of 30 treatment-emergent adverse events (EAE) were reported (15 in each group). Three treatment-EAE in the MPFF 1000 mg group ( @entity4 , @entity5 , @entity1 ) were considered by the investigator to be related to treatment. All were of mild intensity and resolved when treatment finished. Both MPFF regimens were associated with a significant reduction in leg @entity3 score with a reduction of 4.21 cm for MPFF 1000 mg once daily (P<0.001) and 4.01 cm for MPFF 500 mg twice daily (p<0.001). The reduction in @entity3 was noted after 2 weeks of treatment and continuously throughout the treatment. CONCLUSIONS: Both treatment regimens were well tolerated and associated with similar reductions in leg @entity3 after 8 weeks of treatment. The new MPFF 1000 mg dose regimen has a similar safety profile to two MPFF 500 mg tablets with the advantage of one tablet per day and potential improved @entity0 adherence.

title: Clinical acceptability study of once-daily versus twice-daily micronized purified @entity6 fraction in @entity0 with symptomatic XXXX : a randomized controlled trial.

answer: @entity2


abstract: UNASSIGNED: The authors present five cases of @entity4 located in the femur (4) and tibia (1) in @entity0 and young adults (1 female and 4 males) with an age range of 9 - 23 years (mean age 15 years). Radiographs in all cases showed a broad-based soft tissue mass attached to the cortex with periosteal reaction and in two of them cortical disruption with extensive medullary involvement. Follow-ups were available in four cases (range 11 - 73 months) and revealed pelvic @entity1 after 15 months with ultimately rapid dissemination and death in a 9-year-old @entity0 and @entity1 to the humerus after 13 months in a 15-year-old @entity0 . The former @entity2 widely extended into the medullary cavity and an amputation was carried out, the latter had a pure juxtacortical position and an en block resection was performed; both of them were treated with chemotherapy. All the lesions displayed distinctive structural patterns combining a large island of tumorous cartilage and hypocellular, bland-looking myxoid mesenchymal stroma with abrupt transition between both components. @entity3 , the delicate @entity7 were produced by innocuous stromal cells lacking apparent atypia. They were strictly situated outside the prevailing chondroid areas and disclosed sometimes only after a meticulous search. Immunohistochemical detection of @entity8 , @entity5 protein and D2-40 assisted effectively not only in recognition of the real stromal histogenetic derivation, but also in distinction of true differentiation of a heavily mineralized extracellular matrix. Molecular analysis revealed no @entity6 mutation in four examined cases. Regardless of unique low-grade morphology in rare @entity4 , an aggressive therapeutical approach similar to @entity3 is justified, particularly in the case of a medullary extension.

title: [ XXXX - personal experience with five cases].

answer: @entity4


abstract: PURPOSE: We evaluated the usefulness of percutaneous reduction and leverage fixation using K-wires in @entity0 with @entity1 . MATERIALS AND METHODS: Between 2006 and 2008, we evaluated 13 paediatric @entity0 with @entity1 who had been observed for at least two years and underwent percutaneous reduction and leverage fixation using K-wires. We measured radial angulation and radial translation using preoperative, postoperative and final follow-up radiographs, and we clinically investigated range of motion and carrying angle according to Steele's grading system. RESULTS: Excellent clinical results were achieved in 11 (84.6%) @entity0 , good results in one (7.6%) and fair results in one (7.6%). There were no poor results. The @entity0 in whom fair results were achieved also had an @entity1 , which was treated conservatively. Complications such as nonunion, @entity2 , @entity4 and periarticular ossification were minimal. @entity5 was absent between the @entity1 and the greenstick fracture of the olecranon. @entity3 in the proximal radial epiphysis was also absent. CONCLUSION: Percutaneous reduction and leverage fixation using K-wires in @entity0 with @entity1 is a recommended surgical treatment that can achieve recovery of normal radial angulation and elbow motion.

title: Percutaneous reduction and leverage fixation using K-wires in XXXX .

answer: @entity1


abstract: BACKGROUND: @entity0 nonadherence to cardiac medications following @entity4 ( @entity4 ) is associated with increased risk of recurrent events. However, the prevalence of @entity1 and poor health literacy among @entity4 @entity0 and their association with medication nonadherence are poorly understood. METHODS: We assessed rates of @entity1 and poor health literacy among @entity0 of a clinical trial that tested the effectiveness of an intervention to improve medication adherence in @entity0 hospitalized with @entity4 . Of 254 @entity0 , 249 completed the Rapid Estimate of Adult Literacy in Medicine, Revised (REALM-R) survey, an assessment of risk for poor literacy, and the St Louis University Mental Status (SLUMS) exam, a tool assessing for @entity2 , during @entity4 hospitalization. We assessed if SLUMS or REALM-R scores were associated with medication adherence. RESULTS: Based on SLUMS score, 14% of @entity0 were categorized as having @entity3 , and 52% with @entity2 ( @entity2 ). Based on REALM-R score of  <=6, 34% of @entity0 were categorized as at risk for poor health literacy. There was no association between poor health literacy and medication nonadherence. Of those with @entity2 , 35.5% were nonadherent, compared to 17.5% with normal cognitive function and 6.7% with @entity3 . In multivariable analysis, @entity1 was associated with medication nonadherence (P=0.007), mainly due to an association between @entity2 and nonadherence (odds ratio =12.2, 95% confidence interval =1.9 to 243; P=0.007). Cognitive status was not associated with adherence in @entity0 randomized to the intervention. CONCLUSION: @entity1 and risk for poor health literacy are common in @entity0 hospitalized with @entity4 . We found an association between @entity2 and medication nonadherence in the usual care group but not in the intervention group. These findings suggest efforts to screen for @entity2 are needed during @entity4 hospitalization to identify @entity0 at risk for nonadherence and who may benefit from an adherence intervention.

title: XXXX and poor health literacy are common in veterans presenting with @entity4 : insights from the MEDICATION study.

answer: @entity1


abstract: BACKGROUND: Wide-necked anterior communicating @entity2 represent a subset of lesions with challenging endovascular treatment despite new endoluminal and intrasaccular devices. OBJECTIVE: To assess the long-term clinical and angiographic outcomes of stent-assisted @entity5 for wide-necked anterior communicating @entity2 . METHODS: Between March 2008 and March 2014, 32 @entity0 with unruptured wide-necked AComm @entity3 were treated using stent-assisted @entity5 . The Glasgow Outcome Scale was reviewed at the time of discharge and at latest follow-up. Ischemic and hemorrhagic events were also recorded and analyzed. @entity3 was evaluated post-intervention and on subsequent follow-up evaluations. RESULTS: Successful stent deployment was achieved in all cases, but in 1 @entity0 the coils could not be contained inside the @entity3 , and the procedure was aborted without complications. The distal segment of the stent was positioned in the ipsilateral A2 in 16 @entity0 , in the contralateral A2 in 15 @entity0 , and in the contralateral A1 in 1 @entity0 . There were no periprocedural @entity7 . The rate of major complications was 6%. One @entity0 developed @entity6 related to antiplatelet therapy and another had @entity1 events due to in-stent @entity4 . Angiographic follow-up was available for 26 @entity3 and during a mean follow-up of 22 months, 81% of the lesions were completely occluded and 8% had a small residual neck. The retreatment rate for residual @entity3 was 3%. CONCLUSION: Our long-term results suggest that stent-assisted @entity5 for anterior communicating @entity2 may be considered an excellent treatment option with an adequate combination of safety profile and effectiveness. ABBREVIATIONS: AComm, anterior communicating arteryGOS, Glasgow Outcome ScaleICA, internal carotid arterySAC, stent-assisted coiling.

title: A Reappraisal of Anterior Communicating XXXX : A Case for Stent-Assisted Embolization.

answer: @entity2


abstract: OBJECTIVE: To study serum lipid profile in @entity0 with @entity2 and to determine significant correlation between them. To ascertain the effect of age and sex on serum lipid profile. DESIGN: Case Control study. SETTING: Single Tertiary care centre in Southern India. @entity0 : Total of 100 @entity0 of which 80 were cases of @entity1 (ischaemic--50 and haemorrhagic --30) and the remaining 20 were controls. Males accounted for 71 cases. All subjects were adult @entity0 . @entity0 with suspected emboli of cardiac origin and diabetics (Type 1 and 2) were excluded from the study. None of the @entity0 were on diet or other modification that would lower plasma lipid levels. RESULTS: 32 @entity0 had elevated serum total @entity3 levels, of which 81.3% had @entity1 and the rest @entity5 . 10 @entity0 had elevated serum @entity4 levels, of which 80% had @entity1 and the rest @entity5 . 33 @entity0 had elevated serum low density lipoprotein levels of which 75.8% had @entity1 whereas the remaining had @entity5 . CONCLUSION: A statistically positive correlation was found between serum Total @entity3 , @entity6 , LDL levels and the risk of @entity1 .

title: Lipid profile in non-diabetic XXXX --a study of 100 cases.

answer: @entity1


abstract: BACKGROUND: The association of primary Sj  gren  @entity1 ( @entity1 ) and @entity5 has been recognized but scarcely assessed. OBJECTIVE: Herein we analyzed the literature regarding this association in order to describe a @entity1 phenotype prone to both conditions. METHODS: PubMed and CINAHL databases were searched from inception until April 2016 for the key words: @entity5 , @entity1 and their combinations. RESULTS: Most of the cases corresponded to @entity5 mainly at skin and lung, whereas only three cases were systemic. Other places of @entity5 were the kidney, @entity8 , breast, salivary gland and vocal cord. Most of the localized forms corresponded to AL type, whereas @entity5 was uncommon. The diagnosis of @entity5 followed the @entity1 onset (1-25 years) and in the majority of @entity0 the presence of B cell @entity6 traduced by @entity7 , positive rheumatoid factor and/or anti-Ro/SSA and anti- @entity9 antibodies were observed. In seven @entity0 , an associated @entity2 was also documented. CONCLUSION: The spectrum of lymphoid proliferation associated with @entity1 extends beyond the classical @entity4 . Localized or @entity3 might coexist with primary @entity1 . @entity5 should be suspected in @entity0 with consistently high serologic activity and suggestive lesions.

title: Coexistence of @entity5 and Primary Sj  gren's Syndrome: An overview XXXX .

answer: @entity5


abstract: Resistance to @entity4 agonists can be defined with respect to failure to normalize PRL levels and failure to decrease @entity1 size by > or = 50%. Using these definitions, failure to normalize PRL levels is seen in 24% of those treated with @entity6 , 13% of those treated with @entity8 and 11% of those treated with @entity9 . Failure to achieve at least a 50% reduction in @entity1 size occurs in about one-third of those treated with @entity6 and 10-15% of those treated with @entity8 or @entity9 . Studies of in vitro cell preparations show that the D2 receptors of resistant @entity1 are decreased in number but have normal affinity. Treatment approaches for resistant @entity0 include switching to another @entity4 agonist and raising the dose of the drug as long as there is continued response to the dose increases and no adverse effects. Transsphenoidal surgery can also be done. If fertility is desired, @entity7 , gonadotropins, and @entity5 are also options. If fertility is not desired, @entity2 replacement may be used unless there is a macroadenoma, in which case control of @entity1 growth is also an issue and @entity4 agonists are generally necessary. However, in many cases modest or even no reduction may be acceptable long-term as long as there is not @entity1 growth. Hormone replacement ( @entity2 or @entity3 ) may cause a decrease in efficacy of the @entity4 agonist so that it must be carried out cautiously. Reduction of endogenous @entity2 , use of selective @entity2 receptor modulators, and aromatase inhibitors are potential experimental approaches.

title: XXXX resistance of prolactinomas.

answer: @entity4


abstract: The prognostic value of @entity4 early after @entity7 ( @entity7 ) is still controversial, depending on the @entity0 under study and the outcome end point considered. Furthermore, the relative prognostic importance of viability compared with indicators of @entity9 is not known. One hundred thirty-eight @entity0 were studied with low-dose @entity6 echocardiography 3 +/- 1 days after @entity7 . @entity0 were divided in 2 groups based on presence (n = 55) or absence (n = 83) of @entity4 and followed up for in-hospital and late @entity5 . During hospitalization, @entity4 was the only independent predictor for recurrent @entity1 events (chi-square 5.0, p = 0.025). End-systolic volume index and ejection fraction were both independent predictors of the occurrence of @entity8 , whereas gender and end-systolic volume index emerged as independent predictors of hard @entity5 ( @entity3 and sustained @entity10 ). After hospital discharge, @entity0 were followed for 19 +/- 7 months. Again, @entity4 emerged as the only independent predictor of @entity11 (chi-square 7.7, p = 0.005). Age, @entity2 , and ejection fraction were the most important independent predictors of hospitalization for @entity8 , whereas ejection fraction was the only independent predictor of hard @entity5 . Presence of @entity4 early after @entity7 is the single best predictor of recurrent in-hospital @entity1 events and @entity11 after discharge. With respect to hard @entity5 and occurrence of @entity8 , indicators of @entity9 have a higher prognostic value than presence of @entity4 .

title: In-hospital and long-term prognostic value of viable myocardium detected by XXXX echocardiography early after @entity7 and its relation to indicators of @entity9 .

answer: @entity6


abstract: BACKGROUND: The management of @entity2 / @entity6 ( @entity5 /MND) has shifted from an attitude of nihilism to treatments that prolong survival and offer hope. Nutrition is an integral component of @entity5 /MND care requiring coordination among acute and community multi-disciplinary teams (MDT). Evidence-based nutrition guidelines exist for this @entity0 group but their use among dietitians is unknown. The aim of this study was to survey the knowledge, practice and guideline use of dietitians working in @entity5 /MND centres/clinics across England, Wales, Northern Ireland (EWNI) and Canada. METHOD: Dietetic contact details were obtained from the Motor Neurone Disease Association (MNDA) and the @entity5 Society of Canada (ALSSC) websites. Telephone interviews were conducted with 23 dietitians using a standardized questionnaire. RESULTS: Multi-disciplinary team membership was high (78%). Only 22% dietitians had >4-years experience in @entity5 /MND care. Dietitians reported using body weight, percentage @entity1 (PWL) and body mass index (BMI) to assess nutritional status. Equations used to estimate energy and protein requirements differed. Most frequent dietary advice was high calorie, texture modification and prescription nutritional supplements. Artificial nutrition and hydration (ANH) was discussed when @entity0 developed @entity4 , energy intake was inadequate, @entity1 of 10% or forced vital capacity (FVC) was reduced. A percutaneous endoscopic gastrostomy ( @entity3 ) service was available at all clinics/centres. CONCLUSION: Nutritional assessment techniques and dietary advice should be standardized. Dietetic collaboration at national and international level is recommended to reduce professional isolation. Training and support in @entity5 /MND nutrition should be made available as part of post-dietetic registration. Further dietetic research is required to stimulate nutritional care.

title: Nutritional advice and treatment by dietitians to @entity0 with XXXX / @entity6 : a survey of current practice in England, Wales, Northern Ireland and Canada.

answer: @entity2


abstract: UNASSIGNED: @entity5 exert important effects on the reproductive as well as many other organ systems in both @entity1 and @entity1 . The history of the discovery of @entity5 , the mechanisms of their synthesis, and their therapeutic applications are very important components of the fabric of endocrinology. These aspects provide the rationale for highlighting several key components of this story. Two investigators, Edward Doisy and Alfred Butenandt, purified and crystalized @entity7 nearly simultaneously in 1929, and Doisy later discovered @entity9 and @entity2 . Butenandt won the Nobel Prize for this work and Doisy's had to await his purification of @entity4 . Early investigators quickly recognized that @entity5 must be synthesized from @entity6 and later investigators called this process aromatization. The aromatase enzyme was then characterized, its mechanism determined, and its structure identified after successful crystallization. With the development of knock-out methodology, the precise effects of @entity5 in males and females were defined and clinical @entity3 and excess described. Their discovery ultimately led to the development of @entity8 , treatment of menopausal symptoms, therapies for @entity0 , and induction of fertility, among others. The history of the use of @entity5 for postmenopausal @entity1 to relieve symptoms has been characterized by cyclic periods of enthusiasm and concern. The individuals involved in these studies, the innovative thinking required, and the detailed understanding made possible by evolving biologic and molecular techniques provide many lessons for current endocrinologists.

title: Celebrating 75 years of XXXX .

answer: @entity2


abstract: From 1988 to 1999, 85 cases of adult @entity1 were admitted to the medical service of Chon Buri Hospital. The male to female ratio was 2.2:1. In 50 @entity0 disease was severe enough to require @entity3 and artificial ventilation. Fourteen @entity0 needed @entity4 and artificial ventilation but not @entity3 ; and in twenty-one the condition was mild, requiring @entity4 only. Eleven @entity0 died, all of them had severe grade of @entity1 . The mortality rate was 12.9 per cent. In 70 @entity0 a wound was the source of @entity2 , most of which were minor, often receiving no medical attention. No wounds or obvious source of @entity2 could be found in 15 @entity0 . @entity1 is a preventable disease. The treatment of @entity1 is time-consuming and costly and there is still a considerable mortality rate. In moderate to severe cases, the @entity0 usually have to spend three to four weeks in an intensive care unit.

title: XXXX in adults: a review of 85 cases at Chon Buri Hospital.

answer: @entity1